Skip to main content

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expands Patient Eligibility for Brain Cancer Drug Trial, Receives Approval from U.S. FDA for Protocol Amendment

  • Novel brain cancer drug developer CNS Pharmaceuticals, Inc. has received approval from the U.S. FDA for a Protocol Amendment that expands patient eligibility for participation in its potentially pivotal Phase 2 clinical trial for a novel drug candidate that targets the nearly 100 percent fatal cancer glioblastoma (“GBM”)
  • CNS is developing the drug candidate Berubicin as an alternative to the standard-of-care chemotherapy agent, Lomustine, with the hope that Berubicin will prove itself at least as effective and potentially more so 
  • Berubicin has demonstrated the capacity to cross the blood-brain barrier in order to attack central nervous system tumors directly, which grants it a novel position since anthracyclines are known for their inability to cross the blood-brain barrier
  • The drug trial is enrolling GBM patients worldwide who have failed to see improvement from the standard of care anthracycline as part of first-line therapy
  • The expansion of the trial allows patients who have perhaps undergone multiple procedures qualified as first-line therapy to participate as well as those who have not undergone the additional procedures
  • The company expects interim results from the study in 2023, primary completion by the end of 2024 and ultimate resolution in the first half of 2025

CNS Pharmaceuticals (NASDAQ: CNSP) is reporting that its global clinical trial for a potentially pivotal brain cancer treatment will expand its patient eligibility following an amendment to its protocol for the study. 

The protocol is a document that describes how the clinical trial will be conducted and ensures the safety of the trial subjects and integrity of the data collected (https://ibn.fm/q6Czx). CNS has been enrolling patients in its potentially pivotal Phase 2 clinical trial for novel drug candidate Berubicin, which has…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.